Judy P. Sy

TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.

TL;DR: Ranibizumab rapidly and sustainably improved vision, reduced the risk of further vision loss, and improved macular edema in patients with DME, with low rates of ocular and nonocular harm.

TL;DR: A 2-year phase III trial designated ANCHOR as discussed by the authors compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV.

TL;DR: Maximum likelihood techniques for the joint estimation of the incidence and latency regression parameters in this model are developed using the nonparametric form of the likelihood and an EM algorithm and are applied to a data set of tonsil cancer patients treated with radiation therapy.

TL;DR: Repeated intravitreal injections of ranibizumab had a good safety profile and were associated with improved VA and decreased leakage from choroidal neovascularization in subjects with neov vascular AMD.